NCT00707707View on ClinicalTrials.gov

Phase I/II Study of AZD2281 Given in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

September 15, 2008

Primary Completion Date

November 9, 2009

Study Completion Date

February 19, 2018

Conditions
Breast CancerTriple Negative Breast CancerMetastatic Breast Cancer
Interventions
DRUG

AZD2281

Dose finding study to establish the appropriate dose of AZD2281

DRUG

Paclitaxel

Intravenous infusion over 1 hour

Trial Locations (6)

1090

Research Site, Vienna

3000

Research Site, Leuven

3050

Research Site, Parkville

4066

Research Site, Auchenflower

6000

Research Site, Perth

M4N 3M5

Research Site, Toronto

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY